StockWatch
·
Biotechnology: Pharmaceutical Preparations
Management ChangeJul 23, 2026, 04:13 PM

Abivax Appoints Four New Commercial Leaders

AI Summary

Abivax announced the expansion of its Commercial Leadership Team with four strategic appointments, including James Berger as Global Head of Marketing, Ivan Nuñez-Pacheco as Global Head of Patient Services, Heather Dean as Global Head of Sales, Accounts & Commercial Operations, and Jeff Haas as Global Head of Market Access & Pricing. These additions aim to strengthen the company's commercial capabilities as it prepares for the potential U.S. commercialization of obefazimod, with a planned New Drug Application (NDA) submission to the FDA in Q4 2026.

Key Highlights

  • Abivax appointed James Berger as Global Head of Marketing, leading commercial strategy for obefazimod.
  • Ivan Nuñez-Pacheco was named Global Head of Patient Services, developing the patient services model for obefazimod.
  • Heather Dean joined as Global Head of Sales, Accounts & Commercial Operations, overseeing sales and operations strategy.
  • Jeff Haas was appointed Global Head of Market Access & Pricing, responsible for market access and pricing strategies.
  • These appointments strengthen the commercial organization ahead of obefazimod's potential U.S. commercialization.
  • The company plans a New Drug Application (NDA) submission to the U.S. FDA in the fourth quarter of 2026.